Featured Studies

Research Study 000444-H investigating how well the following vaccines work in patients with CLL/SLL malignancies: SHINGRIX and influenza vaccine. If you are currently receiving treatment for your CLL/SLL (e.g. ibrutinib, acalabrutinib or venetoclax), you may be able to participate.

Researchers want to see if they can measure the amount of anti-cancer drug, Abemaciclib in a brain tumor and brain fluid after a patient has taken this drug for a few days. These findings can help explain how much drug gets into the brain and how drugs work to shrink high grade gliomas to improve outcomes for these patients.

Researchers at the National Institutes of Health are investigating the role of Near-Infrared Spectroscopy (NIRS) technologies as a monitoring tool for measuring oxygen levels, blood flow, and the make-up of skin and muscle in patients with sickle cell disease (SCD). In this study, researchers will compare NIRS measurements in people with and without SCD.

After stem cell transplantation, some people develop hard-to-treat anemia (low red blood cells) or thrombocytopenia (low platelets). Cytopenia(s) or low blood cell counts make you weak, prone to bleeding and bruising, and dependent on blood product transfusions. Researchers at the National Institutes of Health (NIH) are testing the drug fostamatinib to see if it is safe to treat cytopenia(s) after stem cell transplantation. A physician referral is not required to participate.

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.

A research study at the National Heart Lung and Blood Institute (NHLBI) is looking for pregnant women between 18 and 45 years of age who are at risk of having an infant with sickle cell disease and women who are pregnant with no risk of having an infant with sickle cell to donate their baby's cord blood. Tests and procedures provided at no cost. Travel may be reimbursed.

Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).